Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment

Journal of Clinical Oncology

Volumn 27, Issue 20, 2009, Pages 3379-3384

  Poultsides, George A ^a   Servais, Elliot L ^a   Saltz, Leonard B ^a   Patil, Sujata ^a   Kemeny, Nancy E ^a   Guillem, Jose G ^a   Weiser, Martin ^a   Temple, Larissa K F ^a   Wong, W Douglas ^a   Paty, Phillip B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COLON RESECTION; COLORECTAL CANCER; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LAPAROTOMY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; STENT; TUMOR LOCALIZATION; TUMOR PERFORATION; COHORT ANALYSIS; COLORECTAL TUMOR; FACTUAL DATABASE; METHODOLOGY; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; STATISTICS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70249148634     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.9817     Document Type: Article

References (23)

1. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
2. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
3. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
4. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
5. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005
6. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
7. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
8. Maindrault-Goebel F, Louvet C, Andre T, et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6): GERCOR. Eur J Cancer 35:1338-1342, 1999
9. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
10. The MSKCC Intranet: Information systems: Institutional database, 6/08 update. http://mskweb5 .mskcc.org/intranet/html/12841.cfm
11. D'Angelica M: Are patients with multiple hepatic metastases from colorectal cancer candidates for surgery? Nat Clin Pract Oncol 4:682-683, 2007
12. Temple LK, Hsieh L, Wong WD, et al: Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 22:3475-3484, 2004
13. Cook AD, Single R, McCahill LE: Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of Surveillance, Epidemiology, and End Results data, 1988 to 2000. Ann Surg Oncol 12:637-645, 2005
14. Tebbutt NC, Norman AR, Cunningham D, et al: Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 52:568-573, 2003
15. Ruo L, Gougoutas C, Paty PB, et al: Elective bowel resection for incurable stage IV colorectal cancer: Prognostic variables for asymptomatic patients. J Am Coll Surg 196:722-728, 2003
16. Michel P, Roque I, Di Fiore F, et al: Colorectal cancer with non-resectable synchronous metastases: Should the primary tumor be resected? Gastroenterol Clin Biol 28:434-437, 2004
17. Scoggins CR, Meszoely IM, Blanke CD, et al: Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 6:651-657, 1999
18. Sarela AI, Guthrie JA, Seymour MT, et al: Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 88:1352-1356, 2001
19. Rosen SA, Buell JF, Yoshida A, et al: Initial presentation with stage IV colorectal cancer: How aggressive should we be? Arch Surg 135:530-534, 2000; discussion 534-535
20. Mella J, Biffin A, Radcliffe AG, et al: Population-based audit of colorectal cancer management in two UK health regions: Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg 84:1731-1736, 1997
21. Kemeny MM: Surgery should be the primary treatment of synchronous colorectal metastases in the asymptomatic patient [corrected]. Ann Surg Oncol 13:140-141, 2006
22. Petrelli NJ: Systemic chemotherapy should be the primary treatment of synchronous colorectal metastases in the asymptomatic patient [corrected]. Ann Surg Oncol 13:137-139, 2006
23. National Surgical Adjuvant Breast and Bowel Project: Federally supported clinical trials: Protocol C-10, 6/08 update. http://www.nsabp.pitt.edu/C10- Information.asp